Patterns of use, clinical efficacy, safety and tolerability of Ketamine and Esketamine in treatment-resistant depression: Towards registry-based surveillance systems

J Affect Disord. 2022 Jan 15;297:145-147. doi: 10.1016/j.jad.2021.10.036. Epub 2021 Oct 23.

Abstract

More data on the long-term effects of Racemic Ketamine and Esketamine in TDR patients is needed. The implementation of centralized registries of their use for treatment of depression could be a tool of major importance for assessing their efficacy and safety in real-world clinical practice. This paper seeks to outline the rise and rationale behind these registry-based surveillance systems.

Keywords: Depression; Esketamine; Ketamine; Treatment-resistant depression.

Publication types

  • Letter

MeSH terms

  • Antidepressive Agents / adverse effects
  • Depression
  • Depressive Disorder, Treatment-Resistant* / drug therapy
  • Humans
  • Ketamine* / adverse effects
  • Registries
  • Treatment Outcome

Substances

  • Antidepressive Agents
  • Esketamine
  • Ketamine